AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

โ† Trials
๐Ÿงช

Assessment of a Robotic Exoskeleton for Upper Limb Rehabilitation

RecruitingNAAges 18 Years - anyAllUniversity of Liverpool
๐Ÿ’ฌ

In plain words

What the trial is, and whether it could suit you

Rehabilitation robotics has the potential to facilitate rehabilitation at home and empower people with spinal injuries to self-manage increasing their independence and improving their quality of life. The objective of this study is to assess for the first time in the NHS the efficacy of a commercial robotic orthosis for upper limb rehabilitation in patients with spinal cord injury. The device is produced by Myomo (myomo.com) which is an American company. We will be assessing the wearable robotic orthosis also known as robotic exoskeleton in two different neuro-rehabilitation centres: National Spinal injuries Unit in Glasgow (Scotland) and The Robert Jones and Agnus Hunt Orthopaedic Hospital in Oswestry (England). The study will involve nine spinal cord injured tetraplegic inpatients in total. Patients will follow a twelve-week rehabilitation programme with three to four sessions per we

Sign in to get the eligibility rules as simple questions to take to your doctor.

๐Ÿ“‹ Eligibility rules (as published)
Inclusion Criteria: * Age 18+ years. * The levels of C5 C6 Asia C/D would provide individuals with elbow and hand impairment and potentially functional shoulder movements. C7, C8 individuals could also benefit from the hand component of the device. * Some gross shoulder movement at start of the trial to enable changes at the elbow/hand, to have the greatest potential for functional change. * Preservation of hand sensation as base for motor restoration. * Some sitting balance would give the best opportunity for the arm to be released for functional upper limb activity. * EMG (muscle activity) evidence of active finger flexion, extension and elbow flexion extension Grade 1-2. * Minimal or No community functional use of upper limb at start of trial. * Spasticity MAS 1-3/5.
๐Ÿ’Š

What it tests

  • Experimental: Device Intervention
๐Ÿ“

Where

2 sites
Royal National Orthopaedic Hospital (Stanmore)
London, United Kingdom
The Robert Jones and Agnes Hunt Orthopaedic Hospital NHS Foundation Trust
Oswestry, United Kingdom
๐Ÿค Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible โ€” always decide together with your own doctor.
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy